Topic 5 — The IMA203 (anzu-cel) Trial

“Advancing Melanoma Care: Early Identification, Timely Action, and Next-Generation Therapy,” is an educational video series focusing on earlier identification of advanced melanoma, routine HLA-A*02:01 testing, and timely referral to IMA203 (anzu-cel) trial sites. In Topic 5, “The IMA203 (anzu-cel) Trial,” Alison Betof, MD, PhD, FASCO—Director, Melanoma Program, Mark and Mary Stevens Endowed Scholar in Melanoma, and Director, Solid Tumor Cellular Therapy at Stanford University School of Medicine—provides information on the actively enrolling pivotal Phase 3 clinical trial evaluating anzu-cel, a PRAME-directed engineered TCR-T therapy that is a new option for selected patients with advanced melanoma. Topics in this brief educational video include a discussion of the IMA203 (anzu-cel) trial, what is being evaluated, and how anzu-cel works as a PRAME-directed TCR-T therapy. The discussion for the fifth topic will conclude with information on enrollment, key eligibility criteria for the trial, and why patient selection is critical for successful outcomes.